Study identifier:D7913C00070
ClinicalTrials.gov identifier:NCT01785888
EudraCT identifier:N/A
CTIS identifier:N/A
A diagnostic Study of European and Japanese advanced NSCLC patients to evaluate suitable sample types for EGFR testing,
EGFR mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma and non-adenocarcinoma histologies.
N/A
No
-
All
1311
Observational
18 Years - 99 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Locally advanced/metastatic NSCLC pts. Patients(pts.) with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy) | - |